Metrics as of 10/13/2026, 06:54 PM (Berlin time), refresh in progress.
Sareum Holdings Stock
Sareum Holdings plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Stephen Barry Parker DPhil
- Employees
- 5
- Market cap
- £38 M
- IPO
- 11/10/2004
Sareum Holdings plc operates as a specialized pharmaceutical company, primarily focused on discovering and advancing innovative therapeutic compounds for treating both cancer and autoimmune conditions. The firm develops small-molecule drugs, utilizing its proprietary Sareum Kinase Inhibitor Library as its core drug…
Sareum Holdings stock: price history
1D
+0.0%
1W
-8.3%
1M
-14.1%
6M
+71.9%
YTD
+83.3%
1Y
+38.2%
2Y
-1.8%
5Y
-92.0%
10Y
-53.2%
Next earnings date
Next earnings date
26/10/2026 (in 9 days)
Volatility around earnings
~38% stronger price swings than usual
Ask the agents about Sareum Holdings
Sareum Holdings stock metrics
P/E
-7.55
P/B
31.72
EV/EBITDA
-6.6
RETURN ON EQUITY
-138.4%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
95.4%
FLOAT SHARES
132,205,285
AVG. DAILY VOLUME (30D)
266,768
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Sareum Holdings stock
What does Sareum Holdings do?
Sareum Holdings plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Stephen Barry Parker DPhil, the company employs around 5 people.
The IPO was on 11/10/2004; the stock trades on LSE under the ticker SAR.L.
When does Sareum Holdings report next?
The next earnings date is 26/10/2026.
Around past earnings, price swings were roughly 38% stronger than usual.
Does Sareum Holdings pay a dividend?
No, Sareum Holdings currently does not pay a dividend.
Which stocks are comparable to Sareum Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Sareum Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Sareum Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.